Fate Therapeutics Inc (FATE)

[jondoeuk]

ASH abstracts

2000 Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies https://ash.confex.com/ash/2022/webprogram/Paper167194.html

2004 Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma https://ash.confex.com/ash/2022/webprogram/Paper166994.html

4639 A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma https://ash.confex.com/ash/2022/webprogram/Paper166728.html

1992 FT555: Off-the-Shelf CAR-NK Cell Therapy Co-Targeting GPRC5D and CD38 for the Treatment of Multiple Myeloma https://ash.confex.com/ash/2022/webprogram/Paper170501.html

4623 A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML https://ash.confex.com/ash/2022/webprogram/Paper168981.html

1986 Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy https://ash.confex.com/ash/2022/webprogram/Paper167139.html

481 Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection https://ash.confex.com/ash/2022/webprogram/Paper163086.html

3288 iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma https://ash.confex.com/ash/2022/webprogram/Paper169817.html

3308 A CD3 Fusion Receptor (CD3-FR) Uniquely Enables Compatibility of Allogeneic CAR-T and -NK Cells with T Cell Engagers to Enhance Antitumor Function and Limit Antigen Escape https://ash.confex.com/ash/2022/webprogram/Paper169887.html

4605 Multi-Antigen Targeting By Novel Combination of CAR-T Cells and hnCD16 Transgene, Yields in Complete Tumor Clearance Via Antibody Dependent Cellular Cytotoxicity https://ash.confex.com/ash/2022/webprogram/Paper169462.html

4624 The Development of Allogeneic Tips-Derived TCR- CAR+ CD8aß T Cells https://ash.confex.com/ash/2022/webprogram/Paper169375.html

1218 Characterization of Engineered Macrophages and Other Myeloid Cells Differentiated from CD34+ Hematopoietic Progenitor Cells Derived from Pluripotent Stem Cells https://ash.confex.com/ash/2022/webprogram/Paper170231.html

2045 High-Density Cryopreservation of Off-the-Shelf CAR-NK Cells Facilitates On-demand Treatment Access https://ash.confex.com/ash/2022/webprogram/Paper162712.html

2532 CD82 Is Sufficient to Uniquely Identify Pluripotent Stem Cell-Derived Hemogenic Endothelium with the Hematopoietic Lineage Potency to Give Rise to Bona Fide Lymphocytes https://ash.confex.com/ash/2022/webprogram/Paper169989.html